DIRS.INFO The most relevant business & tech news

☆ Watch out. These stocks reporting next week are at risk of an earnings blow-up
▼ + stars: | 2024-07-31 | by ( Alex Harring | ) www.cnbc.com time to read: +2 min

Investors should be wary of those stocks that are due to report next week whose lackluster earnings could send their share prices down. While earnings have been mostly positive this quarter, several stocks could bring bad news and trip up investors. To find these, CNBC Pro screened FactSet for companies reporting next week that have seen their earnings estimates cut by 5% or more in the past three- and six months. The gas pipeline stock has seen analysts' earnings per share estimates cut by 5.3% over the past three months and 18.6% over the past six months. Analysts have slashed their per-share earnings outlook by 44% and 51% in the past three and six months, respectively.

Persons: Walt Disney, Eli Lilly, Williams, Wells, Michael Blum, Blum, FactSet, Rockwell Organizations: Caterpillar, Walt, CNBC Pro, Williams Companies, Mosaic, Rockwell Automation, Rockwell Locations: Wells Fargo, Milwaukee

☆ Ozempic predecessor suggests potential for GLP-1 drugs in Alzheimer’s in early trial
▼ + stars: | 2024-07-30 | by ( Meg Tirrell | ) edition.cnn.com time to read: +7 min

“This is the first study that actually looked at a relatively large number of patients for whether there is any neuroprotective effect in Alzheimer’s disease,” Edison said. The trial enrolled predominantly people with mild Alzheimer’s disease, measured by a test known as the Mini-Mental State Examination, a scale that goes up to 30. The GLP-1 drug class also includes Eli Lilly’s Mounjaro and Zepbound, which use the active ingredient tirzepatide, which mimics not just the hormone GLP-1 but another called GIP. But it hasn’t announced any trials of its GLP-1 drugs in Alzheimer’s. GLP-1 drugs can have side effects, though, primarily gastrointestinal problems like nausea and vomiting.

Persons: liraglutide, “, ”, Maria Carrillo, Carrillo, Paul Edison, ” Edison, Edison, Eli Lilly’s Mounjaro, Alzheimer’s Lilly, hasn’t, Lilly, Lars Fruergaard Jorgensen, there’s, Dr, Sanjay Gupta, semaglutide Organizations: CNN, Alzheimer’s Association International Conference, Alzheimer’s Association, Novo Nordisk, Imperial College London, ”, Nordisk, ” Novo Nordisk, CNN Health, University of Oxford, Alzheimer’s Society, Alzheimer’s Locations: United Kingdom, Philadelphia, Alzheimer’s, ” Novo, Danish

☆ Older GLP-1 drug from Novo Nordisk may slow Alzheimer's disease progression by protecting the brain, study says
▼ + stars: | 2024-07-30 | by ( Annika Kim Constantino | ) www.cnbc.com time to read: +5 min

George Frey | ReutersAn older, once-daily drug for diabetes and obesity from Novo Nordisk called liraglutide may slow the progression of Alzheimer's disease by protecting patients' brains, according to data from a mid-stage trial released on Tuesday. Novo Nordisk sells liraglutide as a diabetes and obesity drug under the brand names Victoza and Saxenda, respectively. Alzheimer's disease often causes the brain to shrink as the illness progresses because crucial nerve cells break down and stop working properly. By 2050, the number of Alzheimer's patients is projected to rise to almost 13 million in the U.S. The ongoing EVOKE is examining semaglutide, the active ingredient in Wegovy and Ozempic, in nearly 2,000 Alzheimer's patients.

Persons: George Frey, Eli Lilly, liraglutide, Brian B, Bettencourt, Heather Snyder, Leqembi, Snyder, Dr, Paul Edison, Edison, Bobby Pugh, Bessie Pugh, Karen Pulfer Focht Organizations: Novo Nordisk Pharmaceutical, Reuters, Novo Nordisk, Imperial College London, Alzheimer's Association International Conference, Toronto Star, Getty, Alzheimer's Association, U.S, CNBC, Alzheimer's, Novo Nordisk's, Ave Locations: Provo , Utah, Danish, Philadelphia, Biogen, Novo, Bartlett , Tennessee, U.S

☆ Swiss pharma giant Roche to accelerate Wegovy rival drugs after positive trial data
▼ + stars: | 2024-07-29 | by ( Karen Gilchrist | ) www.cnbc.com time to read: +2 min

Swiss pharmaceutical giant Roche said Monday it is accelerating the development of its Wegovy rival weight loss drugs following promising early stage trial data. However, in an FT interview published earlier Monday, CEO Thomas Schinecker indicated that the firm's first obesity drug could come to market "significantly faster than people are expecting," potentially by 2028. Both CT-388 and CT-996 were acquired as part of Roche's purchase of U.S. biotech company Carmot Therapeutics, which completed in January. The promising results could see Roche emerge as a potential rival to obesity drug pioneers Novo Nordisk and Eli Lilly. Schinecker told CNBC last week that he expects the company to eventually offer a suite of obesity medications.

Persons: Roche, Nordisk's Wegovy, Eli Lilly, Thomas Schinecker, Teresa Graham, Roche's, Schinecker Organizations: Nordisk's, CNBC, Roche Pharmaceuticals, Carmot Therapeutics, Novo Nordisk Locations: U.S

☆ Here are JPMorgan's top drug stock picks into earnings
▼ + stars: | 2024-07-29 | by ( Brian Evans | ) www.cnbc.com time to read: +3 min

JPMorgan is eyeing a few drug manufacturers ahead of their earnings reports as investors continue to sell out of major technology firms. This backdrop has analyst Chris Schott reviewing JPMorgan's top pharmaceutical and biotechnology stocks, which includes "stories that have clear upside potential to longer-term estimates" like Eli Lilly and Merck. Eli Lilly Pharmaceutical company Eli Lilly made the list. Schott said the firm is somewhat below consensus Wall Street estimates for Eli Lilly heading into second-quarter results on Aug. 8. LLY YTD mountain Eli Lilly stock.

Persons: Johnson, Merck —, Chris Schott, Eli Lilly, Merck, Schott, —, Regeneron Organizations: JPMorgan, Dow Jones, Johnson, Merck, US Major Pharma, Schott, FactSet, Pharmaceuticals Locations: Mounjaro, Novo

☆ Here are Monday's biggest analyst calls: Nvidia, Apple, Tesla, Live Nation, 3M, Uber, Eli Lilly, Amazon, Coinbase & more
▼ + stars: | 2024-07-29 | by ( Michael Bloom | ) www.cnbc.com time to read: +6 min

Here are Monday's biggest calls on Wall Street: Morgan Stanley reiterates Live Nation as overweight Morgan Stanley said shares of the entertainment concert company are compelling. " Cantor Fitzgerald reiterates Nvidia as overweight Cantor said the stock is still a top pick at the firm. Guggenheim upgrades Akamai to buy from neutral Guggenheim said shares of the cloud computing networking company have more room to run. Bank of America reiterates Apple as buy Bank of America said it's bullish heading into Apple earnings later this week. JPMorgan reiterates Eli Lilly as overweight JPM said the stock is a "core holding" ahead of earnings on August 8.

Persons: Morgan Stanley, Cantor Fitzgerald, Cantor, TD Cowen, AAPL, Wells, Booz Allen Hamilton, it's, Guggenheim, Piper Sandler, Charles Schwab, Piper, Schwab, Olin, Mizuho, Bill Brown's, Myers Squibb, JPMorgan, Eli Lilly, JPM, Evercore, Tesla, Oppenheimer, Raymond James, Davidson, Raymond James downgrades Organizations: NVDA, MU, Apple, Huawei, Booz, Guggenheim, RBC, Deutsche Bank, Northrop, Deutsche, JPMorgan, Uber, Holdings, 3M, " Bank of America, Bank of America, Edge, Barclays downgrades Bristol, Myers Squibb, Barclays, Bristol, Ford, Microsoft, Charter, HSBC Locations: China, underperform

☆ These drugmakers are catching up to Eli Lilly and Novo Nordisk in weight loss treatments
▼ + stars: | 2024-07-28 | by ( Christina Cheddar Berk | In | ) www.cnbc.com time to read: +6 min

With billions at stake, that's pretty much been a guarantee facing the current market leaders, Eli Lilly and Novo Nordisk , from the start. Their updates are likely to be joined by others in the coming months even as today's incumbents develop their own next-generation weight loss treatments. Other analysts have also grown more optimistic about the future of weight loss treatments. Orforglipron, a once-a-day oral GLP-1 drug that Lilly is working on, had shown a 3% weight loss at 4 weeks. The company is also exploring whether the weight loss treatment could be given only once a month.

Persons: Eli Lilly, drugmakers Roche, Lilly, Denmark's, Trung Huynh, Huynh, Rajesh Kumar, Kumar, Novo, Roche, Roche ADRs, Justin Zelin, Zelin, Viking's, HSBC's Kumar, Novo aren't, —, Nick Wells Organizations: Novo Nordisk, Viking Therapeutics, UBS, HSBC Global Research, Carmot Therapeutics, Food and Drug Administration, Viking, European Association for, Diabetes, Pfizer, Amgen, Therapeutics Locations: Swiss, Novo, San Antonio, Spain

☆ Beyond Novo and Eli Lilly: Watch these biotech and weight loss drug names, fund manager says
▼ + stars: | 2024-07-26 | by ( Weizhen Tan | ) www.cnbc.com time to read: +3 min

Weight loss drugs have drawn investor interest and shaken up other sectors in the past year or so. Novo Nordisk and Eli Lilly were two early winners of this trend, as their drugs dominate the weight loss drug market. Yuri Khodjamirian, fund manager at Tema ETFs, said both companies are a "very powerful duopoly." They're a lot more risky than the bigger ones who already have drugs on the market," Khodjamirian said. Tema ETFs offers actively managed exchange-traded funds, with a focus on health care and life sciences.

Persons: Eli Lilly, Yuri Khodjamirian, Goldman Sachs, Khodjamirian, Roche Organizations: Novo Nordisk, Tema, CNBC, Zealand Pharma, Viking Therapeutics, Tema Oncology, Mental Health Locations: Tema

☆ 10 things to watch in the stock market Friday after a tumultuous week
▼ + stars: | 2024-07-26 | by ( Jeff Marks | ) www.cnbc.com time to read: +3 min

The data didn't sway the market odds on the Fed cutting interest rates three times this year, starting in September. The industrial conglomerate raised its full-year outlook. Two of the Club's industrial names, Honeywell and Dover , reported earnings this week with mixed fortunes for their stocks. Dexcom shares plunged more than 35% after the medical device company missed on revenue and cut its full-year outlook. Jim waits 45 minutes after sending a trade alert before buying or selling a stock in his charitable trust's portfolio.

Persons: Bristol Myers, Abbott, Skechers, Lockheed Martin, L3Harris, Japan's Eisai, Eli Lilly, Jim Cramer's, Jim Cramer, Jim Organizations: Nasdaq, Federal, Transportation, Electronics, Honeywell, Colgate, Palmolive, Abbott Laboratories, Libre, Deutsche Bank, Lockheed, EU, Novo Nordisk, Jim Cramer's Charitable, CNBC Locations: Dover

☆ European drug regulator rejects Alzheimer's treatment Leqembi from Biogen, Eisai
▼ + stars: | 2024-07-26 | by ( Annika Kim Constantino | ) www.cnbc.com time to read: +2 min

European drug regulators on Friday rejected the Alzheimer's treatment Leqembi from Biogen and Eisai , creating another hurdle for the companies as they scramble to boost uptake of the therapy in the U.S. But it almost always follows the drug regulator's recommendations. The European Medicines Agency's human medicines committee recommended against granting marketing authorization for Leqembi. Leqembi and Kisunla are milestones in the treatment of Alzheimer's after three decades of failed efforts to develop medicines that can fight the fatal disease. In 2021, the European Medicines Agency rejected Aduhelm.

Persons: Eisai, Leqembi, Eli Lilly, Kisunla, Aduhelm Organizations: U.S, European Commission, U.S . Food, Drug Administration, Medicines, European Medicines Agency, Alzheimer's Locations: Biogen, U.S, Japan, South Korea, China, Israel, Europe, Alzheimer's Europe

☆ Wegovy rival to be part of a suite of weight loss drugs, Roche CEO says following positive trial results
▼ + stars: | 2024-07-25 | by ( Karen Gilchrist | ) www.cnbc.com time to read: +1 min

Roche said Thursday that its Wegovy rival weight loss drugs will be part of a suite of medicines aimed at combatting the effects of obesity. CEO Thomas Schinecker welcomed positive early stage trial results from the firm's two weight loss drug candidates as showing "best in disease potential." "We do believe we have two next generation GLP-1/GIPs that have a best in disease potential," he said of the obesity drugs. GLP-1s, or glucagon-like peptide 1 agonists, are a group of drugs used to treat diabetes and obesity. They form the basis of weight loss drugs such as Novo Nordisk's Wegovy and Eli Lilly's Zepbound.

Persons: Roche, Thomas Schinecker, Schinecker, CNBC's, Nordisk's Wegovy, Eli Lilly's Zepbound Organizations: Nordisk's

☆ Viking Therapeutics stock jumps 30% after drugmaker moves weight loss injection to late-stage trial
▼ + stars: | 2024-07-25 | by ( Annika Kim Constantino | ) www.cnbc.com time to read: +2 min

Shares of Viking Therapeutics jumped more than 30% on Thursday after the biotech company a day earlier announced plans to advance its experimental weight loss injection into a late-stage trial earlier than expected. Viking is one of several small and large drugmakers hoping to compete in the space against Novo Nordisk and Eli Lilly , whose weight loss and diabetes GLP-1s have skyrocketed in demand over the last two years. During the call, Lian added that Viking expects to test VK2735 as a monthly injection in a future study. Viking Therapeutics' drug promotes weight loss by targeting a GLP-1 and another hormone called GIP. That pill caused 3.3% weight loss when compared to a placebo in an early-stage trial.

Persons: Eli Lilly, Viking, Brian Lian, Lian, Justin Zelin, Zelin, Eli Lilly's Zepbound Organizations: Viking Therapeutics, San, Novo Nordisk, Food and Drug Administration, FDA, Novo Nordisk's Wegovy Locations: San Diego

☆ Alphabet moves past early stumbles in AI to deliver positive story to investors
▼ + stars: | 2024-07-23 | by ( Zev Fima | ) www.cnbc.com time to read: +12 min

Strong numbers in the company's search and cloud businesses more than offset the slight misses in the YouTube and network units. Cloud recorded a couple of big firsts: exceeding $10 billion in revenue, along with $1 billion in operating income. Whereas investors were — and many still are — concerned about what generative AI might mean for Alphabet's search revenue, the opposite appears to be the case, at least for now. Google Cloud revenue grew roughly 28% to more than $10 billion for the first time. Strong numbers in the company's search and cloud businesses more than offset the slight misses in the YouTube and network units.

Persons: we're, capex, Sundar Pichai, Pichai, Philipp Schindler, Schindler, Ruth Porat, Eli Lilly, Anat Ashkenazi, Jim Cramer's, Jim Cramer, Jim, Loren Elliott Organizations: YouTube, Microsoft, Club, Nvidia, Lens, CTV, Nielsen, Google, buybacks, CNBC, Government, Society, Calif, Bloomberg, Getty, Meta Locations: That's, U.S, Stanford

☆ How CrowdStrike's stumble could impact our cybersecurity stock Palo Alto
▼ + stars: | 2024-07-19 | by ( Kevin Stankiewicz | ) www.cnbc.com time to read: +3 min

Every weekday the CNBC Investing Club with Jim Cramer holds a "Morning Meeting" livestream at 10:20 a.m. Shares of Club holding Palo Alto Networks rose more than 1% Friday after an update from its cybersecurity rival CrowdStrike caused a widespread IT outage across the globe. As a subscriber to the CNBC Investing Club with Jim Cramer, you will receive a trade alert before Jim makes a trade. THE ABOVE INVESTING CLUB INFORMATION IS SUBJECT TO OUR TERMS AND CONDITIONS AND PRIVACY POLICY , TOGETHER WITH OUR DISCLAIMER . NO FIDUCIARY OBLIGATION OR DUTY EXISTS, OR IS CREATED, BY VIRTUE OF YOUR RECEIPT OF ANY INFORMATION PROVIDED IN CONNECTION WITH THE INVESTING CLUB.

Persons: Jim Cramer, CrowdStrike, Nikesh Arora, Jeff Marks, Jeff, Eli Lilly, Jim, Lilly, Roche, Eli Lilly's, Jim Cramer's Organizations: CNBC, Nasdaq, Dow Jones, Palo Alto Networks, Palo Alto, Novo Nordisk Locations: Danish

☆ Which Weight Loss Drug Should You Choose (if You Get to Choose)?
▼ + stars: | 2024-07-19 | by ( Gina Kolata | ) www.nytimes.com time to read: +1 min

People with obesity now have a choice between two powerful drugs to help them lose weight. One is semaglutide, sold by Novo Nordisk as Wegovy for obesity treatment and as Ozempic for diabetes. A recent study suggested that people lost more weight taking Mounjaro than they did taking Ozempic, and it may leave you wondering: Which should I take? Is one weight loss drug really better than the other? All of the information available comes from “highly flawed studies,” said Dr. Diana Thiara, medical director of the weight loss clinic at the University of California, San Francisco.

Persons: Eli Lilly, I’m, ”, Diana Thiara Organizations: Novo Nordisk, University of California Locations: San Francisco

☆ 10 things to watch in the stock market Friday, including tech rotation and Eli Lilly approval
▼ + stars: | 2024-07-19 | by ( Jeff Marks | ) www.cnbc.com time to read: +4 min

10 things to watch Friday, July 19 Can tech stocks and the overall market stabilize to end the week? That's what to watch after a brutal week for the "Magnificent Seven," which fell victim to a rotation away from 2024 winners. PPG Industries lowered its organic sales growth outlook, putting pressure on the stock. The credit card giant, known for its affluent customer base, also lifted its 2024 earnings outlook. As a subscriber to the CNBC Investing Club with Jim Cramer, you will receive a trade alert before Jim makes a trade.

Persons: CrowdStrike, Piper Sandler, Halliburton, SLB, Eli Lilly, Morgan Stanley, Bill Newlands, Jim Cramer's, Jim Cramer, Jim Organizations: Nasdaq, Palo Alto Networks, Netflix, JPMorgan, PPG Industries, American Express, Novo Nordisk, Arm Holdings, Barclays, Molson Coors, Constellation Brands, Modelo, Corona, Jim Cramer's Charitable, CNBC Locations: Palo, China

☆ Jim Cramer supports megacaps for the long term, even as Wall Street continues to sell
▼ + stars: | 2024-07-18 | by ( Julie Coleman | ) www.cnbc.com time to read: +1 min

As megacaps continue to decline, CNBC's Jim Cramer said he remains optimistic about their prospects in the long run. "You just need to get over the hump, a hump that periodically scares people out of this whole asset class." Cramer said he always encourages investors take profits on winners when they can, otherwise it's possible to "get obliterated." And owning losers can feel more difficult than owning winners because it's more obvious why the latter might be on the decline, he added. Cramer said the arguments against these stocks are "for real," but similar to what has been said about them for years.

Persons: megacaps, CNBC's Jim Cramer, Cramer, Eli Lilly Organizations: Meta, Microsoft, Nvidia, Tesla

☆ Novo Nordisk, Eli Lilly have strong first-mover advantage in weight loss drug market, analyst says
▼ + stars: | 2024-07-18 | by ( ) www.cnbc.com time to read: 1 min

Share Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailNovo Nordisk, Eli Lilly have strong first-mover advantage in weight loss drug market, analyst saysEmily Field, head of European pharmaceuticals research at Barclays, says it's too early to say what the competitive landscape will look like in five years for the weight loss drug market, as many trials are still in an early stage.

Persons: Eli Lilly, Emily Field, it's Organizations: Novo Nordisk, Barclays

☆ We're upgrading Eli Lilly after an overdone sell-off on competition fears
▼ + stars: | 2024-07-18 | by ( Jeff Marks | ) www.cnbc.com time to read: +3 min

Every weekday, the CNBC Investing Club with Jim Cramer releases the Homestretch — an actionable afternoon update, just in time for the last hour of trading on Wall Street. Upgrading Lilly: Shares of Eli Lilly have been hit hard since making a new closing high on Monday. As a subscriber to the CNBC Investing Club with Jim Cramer, you will receive a trade alert before Jim makes a trade. THE ABOVE INVESTING CLUB INFORMATION IS SUBJECT TO OUR TERMS AND CONDITIONS AND PRIVACY POLICY , TOGETHER WITH OUR DISCLAIMER . NO FIDUCIARY OBLIGATION OR DUTY EXISTS, OR IS CREATED, BY VIRTUE OF YOUR RECEIPT OF ANY INFORMATION PROVIDED IN CONNECTION WITH THE INVESTING CLUB.

Persons: Jim Cramer, Eli Lilly, Roche, there's, Lilly, we'll, Jim Cramer's, Jim Organizations: CNBC, Nasdaq, Energy, Nvidia, Lilly, Novo Nordisk, Netflix, PPG Industries, American, Halliburton, Jim Cramer's Charitable Locations: Swiss

Here's a rapid-fire update on all 34 stocks in Jim Cramer's Charitable Trust, the portfolio we use for the CNBC Investing Club. Costco : While Costco gets nearly 7% of its sales from China, Jim said it's unlikely its business would be threatened by geopolitics given the company's popularity in the country. Constellation Brands : There's no doubt that the Modelo and Corona parent is a less attractive stock under Trump compared with Biden. As a subscriber to the CNBC Investing Club with Jim Cramer, you will receive a trade alert before Jim makes a trade. Jim waits 45 minutes after sending a trade alert before buying or selling a stock in his charitable trust's portfolio.

Persons: Jim Cramer's, Jim, Donald Trump, Abbott's, Reckitt Benckiser, we're, there's, it's, Biden, Dupont, Trump, Walt Disney, Nelson Peltz, Jim said, Estee Lauder, Eaton, Honeywell's, Washington that's, Eli Lilly, Roche, Eli Lilly's, Lilly, Sen, J.D, Vance of, Morgan Stanley, ChatGPT, chipmaker, Laxman Narasimhan, Stanley Black, Decker, rightsizing, Wells, Wynn, he's, Jim Cramer, Brendan McDermid Organizations: Jim Cramer's Charitable Trust, CNBC, Trump, Abbott Laboratories, AMD, Broadcom, VMWare, Costco, Coterra Energy, White, Bloomberg, Federal, Motors, Ford, GE Healthcare, Big Tech, Honeywell, Air Products, Linde, Meta, Microsoft, Investors, OpenAI, Republican, Palo Alto Networks, Palo, Procter & Gamble, Biden, Constellation Brands, Modelo, The, TJX, Wynn Resorts, Club, Jim Cramer's Charitable, Traders, New York Stock Exchange Locations: China, Dover, U.S, Washington, Vance of Ohio, Meta, Taiwan, Israel, Gaza, Corona, Wells Fargo, Macau, New York City

☆ Shares of this controversial health-care stock poised to break out to new high, according to the charts
▼ + stars: | 2024-07-16 | by ( Todd Gordon | ) www.cnbc.com time to read: +3 min

Shares of Hims & Hers (HIMS) , a digital consumer-facing health-care company, look poised to break out to a new all time high, according to the charts. HIMS announced in May a controversial weight loss injection product to compete with Lilly's Ozempic and Novo Nordisk's Wegovy. HIMS is not only marketing weight loss drugs, it has over one million subscribers using a wide variety of treatments. It's no secret that the total addressable market for weight loss drugs is gigantic. he volume was massive that day at over 70 million shares traded with average daily volume at round 18 million.

Persons: Howard Marks, HIMS, Lilly's, We've, Goldman Sachs, Eli Lilly's, Todd Gordon, Gordon Organizations: Capital Management, Novo Nordisk's Wegovy, Edge, Inside Edge, CNBC, NBC UNIVERSAL

☆ Cramer's Lightning Round: Don't sell Match Group
▼ + stars: | 2024-07-16 | by ( Julie Coleman | ) www.cnbc.com time to read: +2 min

Stock Chart Icon Stock chart icon Fortinet's year-to-date stock performance. Stock Chart Icon Stock chart icon Sarepta Therapeutics' year-to-date stock performance. Stock Chart Icon Stock chart icon Toast's year-to-date stock performance. Stock Chart Icon Stock chart icon Teva Pharmaceutical's year-to-date stock performance. Stock Chart Icon Stock chart icon Viking Holdings' year-to-date stock performance.

Persons: Palo, Linde's, you've, You've, there's, Teva, Eli Lilly, Jim Cramer's Organizations: Charitable Trust, Products, Air Products, Therapeutics, Sarepta Therapeutics, BJ's Wholesale, Costco, ., Teva, Viking Holdings, Royal Locations: Palo Alto, Linde, Royal Caribbean

☆ CNBC Pro Talks: From weight loss drugs to AI winners, CIO set to reveal his top stocks
▼ + stars: | 2024-07-16 | by ( ) www.cnbc.com time to read: +2 min

Weight loss drugs and artificial intelligence have been dominating headlines, with investors betting that stocks in both categories have big potential upside. On Wednesday's Pro Talks , CNBC's Senior Technology Correspondent Arjun Kharpal will ask Tema ETFs' Yuri Khodjamirian how to best invest in these areas and more. Tema ETFs offers actively managed ETFs, with a focus on healthcare and life sciences. Before Tema ETFs, Khodjamirian spent over a decade at Majedie Asset Management, overseeing U.K. and global portfolios. Click here to join CNBC Pro Talks on Wednesday, July 17, at 7 a.m.

Persons: Arjun Kharpal, Yuri Khodjamirian, Eli Lilly, he'll, Khodjamirian Organizations: Tema, Novo Nordisk, pharma, Majedie Asset Management, Income, CNBC, Nvidia, Scotiabank Locations: Tema, —, U.S, U.K, India

☆ A famed economist who called the 2008 recession shares 5 signs the US is on the brink of a downturn — all while the stock market shows concerning weakness beneath the surface of record highs
▼ + stars: | 2024-07-13 | by ( William Edwards | ) www.businessinsider.com time to read: +5 min

But don't bet on a soft landing outcome for the US economy as the Fed gets set to cut rates, says famed economist David Rosenberg. AdvertisementRosenberg ResearchRosenberg's downbeat views on the labor market come amid his skepticism about the impressive rallies in major stock-market indexes like the Nasdaq 100 and the S&P 500. Still, as Rosenberg points out, some say the Fed needs to act urgently as the labor market weakens. Waiting too long to lower interest rates to support the economy will only increase the odds of the job market breaking down." Rosenberg has been consistently bearish on the US economy in recent months, while the labor market has continued to prove him wrong.

Persons: —, David Rosenberg, Rosenberg, Merrill Lynch's, Eli Lilly, Russell, Neil Dutta, Dutta Organizations: Service, Fed, Rosenberg Research, Business, Bureau of Labor Statistics ', Survey, Nasdaq, Nvidia, Microsoft, Meta, Macro

☆ What's driving Friday's big market comeback, a day after heavy tech selling
▼ + stars: | 2024-07-12 | by ( Matthew J. Belvedere | ) www.cnbc.com time to read: +5 min

Green day : A lot was working in the stock market on Friday. But it was hard to see through an ugly rotation out of this year's Big Tech winners in favor of more interest rate-sensitive stocks. Many of our hot tech stocks took a breather this week. It's more evidence of why Jim Cramer calls these two names "own, don't trade" stocks. As a subscriber to the CNBC Investing Club with Jim Cramer, you will receive a trade alert before Jim makes a trade.

Persons: Jim Cramer, Dow, Russell, Eli Lilly, Lilly, Wells Fargo, NII, toolmaker Stanley Black, Decker, Morgan Stanley, That's, Jim Cramer's, Jim Organizations: CNBC, Big Tech, Federal, Nasdaq, PPI, Fed, Meta, Nvidia, Apple, Ford, Abbott Laboratories, Jim Cramer's Charitable, Financial, Nurphoto, Getty Locations: Morphic, Wells, New York City, Mairo

Search resuls for: "Eli Lilly"

25 mentions found